Mara Cruellas
YOU?
Author Swipe
View article: <scp> Performance of upper gastrointestinal endoscopy in <i>CDH1</i> germline pathogenic variant carriers </scp> : A multicenter study
<span> Performance of upper gastrointestinal endoscopy in <i>CDH1</i> germline pathogenic variant carriers </span> : A multicenter study Open
Hereditary diffuse gastric cancer (HDGC) is a syndrome primarily caused by pathogenic variants in the CDH1 gene, characterized histologically by the presence of signet ring cell carcinoma (SRCC). This observational multicenter study aimed …
View article: Revisiting Alma Ata: A Blueprint for Cancer Care
Revisiting Alma Ata: A Blueprint for Cancer Care Open
Despite significant advances in oncology, cancer care globally continues to face critical challenges, including stark disparities in access, insufficient preventive focus, fragmented primary health care (PHC) integration, unsustainable fin…
View article: A randomized study of 2 risk assessment models for individualized breast cancer risk estimation
A randomized study of 2 risk assessment models for individualized breast cancer risk estimation Open
Background Estimating breast cancer risk involves quantifying genetic and non-genetic factors. This supports health interventions and risk communication to ensure adherence to screening recommendations. This study evaluated the change in r…
View article: Off-label use of olaparib in uncommon tumor locations in patients with impaired homologous recombination genes
Off-label use of olaparib in uncommon tumor locations in patients with impaired homologous recombination genes Open
There is limited published evidence on the use of olaparib in patients harboring pathogenic variants other than breast cancer genes, like PALB2 and ATM and conditions different than those authorized such as digestive tract, neuroendocrine …
View article: Impact of antibiotics, corticosteroids, and microbiota on immunotherapy efficacy in patients with non-small cell lung cancer
Impact of antibiotics, corticosteroids, and microbiota on immunotherapy efficacy in patients with non-small cell lung cancer Open
Lung cancer is a leading cause of morbidity and mortality globally, with its high mortality rate attributed mainly to non-small cell lung cancer (NSCLC). Although immunotherapy with immune checkpoint inhibitors (ICI) has revolutionized its…
View article: The psychosocial impact of prostate cancer screening for <i>BRCA1</i> and <i>BRCA2</i> carriers
The psychosocial impact of prostate cancer screening for <i>BRCA1</i> and <i>BRCA2</i> carriers Open
Objectives To report the long‐term outcomes from a longitudinal psychosocial study that forms part of the ‘Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted Screening in men at higher genetic risk and control…
View article: 166P Clinical use of tumor sequencing for identification of germline pathogenic variants (gPV) in breast cancer (BC): The SEQ project
166P Clinical use of tumor sequencing for identification of germline pathogenic variants (gPV) in breast cancer (BC): The SEQ project Open
The aim of this study is to assess the performance of the accredited in-house NGS panel VHIO300 in the detection of gPV in tumor sequencing from patients with BC. We selected 90 patients (pts) with BC with prior germline genetic diagnosis …
View article: Association between missense variants of uncertain significance in the CHEK2 gene and hereditary breast cancer: a cosegregation and bioinformatics analysis
Association between missense variants of uncertain significance in the CHEK2 gene and hereditary breast cancer: a cosegregation and bioinformatics analysis Open
Inherited mutations in the CHEK2 gene have been associated with an increased lifetime risk of developing breast cancer (BC). We aim to identify in the study population the prevalence of mutations in the CHEK2 gene in diagnosed BC patients,…
View article: Impact of Antibiotics, Corticosteroids, and Microbiota on Immunotherapy Efficacy in Patients with Non-Small Cell Lung Cancer
Impact of Antibiotics, Corticosteroids, and Microbiota on Immunotherapy Efficacy in Patients with Non-Small Cell Lung Cancer Open
Lung cancer is a leading cause of morbidity and mortality globally, with its high mortality rate attributed mainly to non-small cell lung cancer (NSCLC). Although immunotherapy with immune checkpoint inhibitors (ICI) has revolutionized its…
View article: 115P Longterm prognostic utility of 70-gene signature by clinical and genomic risks, including Ultralow (gUL) risk patients (pts)
115P Longterm prognostic utility of 70-gene signature by clinical and genomic risks, including Ultralow (gUL) risk patients (pts) Open
In the MINDACT trial, 4 risk categories (RC) by clinical (c) and genomic (g) risks were defined. In cHigh/gLow risk patients (pts) with no adjuvant chemotherapy (CT), 8y-Distant Metastases Free Survival (DMFS) was 89.4 % [95% CI 86.2-91.5]…
View article: Genetic and functional homologous repair deficiency as biomarkers for platinum sensitivity in TNBC: A case report
Genetic and functional homologous repair deficiency as biomarkers for platinum sensitivity in TNBC: A case report Open
Triple-negative breast cancer is the most aggressive subtype of mammary carcinoma. In the early stage, neoadjuvant chemotherapy (NAC) is the standard of care for prognostic stratification and the best adjuvant treatment strategy. A 30-year…
View article: From Tumor Mutational Burden to Blood T Cell Receptor: Looking for the Best Predictive Biomarker in Lung Cancer Treated with Immunotherapy
From Tumor Mutational Burden to Blood T Cell Receptor: Looking for the Best Predictive Biomarker in Lung Cancer Treated with Immunotherapy Open
Despite therapeutic advances, lung cancer (LC) is one of the leading causes of cancer morbidity and mortality worldwide. Recently, the treatment of advanced LC has experienced important changes in survival benefit due to immune checkpoint …
View article: Microbiota and Lung Cancer. Opportunities and Challenges for Improving Immunotherapy Efficacy
Microbiota and Lung Cancer. Opportunities and Challenges for Improving Immunotherapy Efficacy Open
The advances in molecular biology and the emergence of Next Generation Sequencing (NGS) have revealed that microbiome composition is closely related with health and disease, including cancer. This relationship affects different levels of c…
View article: Intratumoral versus Circulating Lymphoid Cells as Predictive Biomarkers in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: Is the Easiest Path the Best One?
Intratumoral versus Circulating Lymphoid Cells as Predictive Biomarkers in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: Is the Easiest Path the Best One? Open
The molecular and cell determinants that modulate immune checkpoint (ICI) efficacy in lung cancer are still not well understood. However, there is a necessity to select those patients that will most benefit from these new treatments. Recen…
View article: Thermal liquid biopsy as a new tool for lung cancer patients diagnostic: Pilot study
Thermal liquid biopsy as a new tool for lung cancer patients diagnostic: Pilot study Open
Background: Thermal Liquid Biopsy (TLB) is based on Differential Scanning Calorimetry (DSC, calorimetric thermogram analysis of serum samples) as a new clinical approach for diagnostic assessment of lung cancer patients. DSC is highly sens…